

Review

Christoph Buchta*, Barbara De la Salle, Rachel Marrington, Andrés Aburto Almonacid, Stéphanie Albarède, Tony Badrick, David Bullock, Christa M. Cobbaert, Wim Coucke, Vincent Delatour, Ana Paula Faria, Wolf-Jochen Geilenkeuser, Andrea Griesmacher, Jim F. Huggett, Viktoriia Ianovska, Martin Kammel, Anja Kessler, Günther F. Körmöczi, Piet Meijer, Armandina Miranda, Dina Patel, Paola Pezzati, Sverre Sandberg, Harald Schennach, Christian R. Schweiger, Karin Schwenoha, Michael Spannagl, Heungsung Sung, Marc Thelen, Cas Weykamp, Heinz Zeichhardt, Veronica Restelli and Lucy A. Perrone

Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA)

Part V – Benefits for stakeholders other than participants

<https://doi.org/10.1515/cclm-2024-1293>

Received November 5, 2024; accepted December 2, 2024;

published online January 6, 2025

Abstract: External quality assessment (EQA) enhances patient safety through the evaluation of the quality of

laboratory-based and point of care testing. Regulatory agencies and accreditation organizations utilize the results and the laboratory's response to them as part of assessing the laboratory's fitness to practice. In addition, where EQA samples are commutable and the assigned value

***Corresponding author: Christoph Buchta**, Austrian Association for Quality Assurance and Standardization of Medical and Diagnostic Tests (ÖQUASTA), Hörigasse 18/5, 1090 Vienna, Austria,

E-mail: christoph.buchta@oequasta.at. <https://orcid.org/0000-0002-4153-8195>

Barbara De la Salle, UK National External Quality Assessment Scheme (UK NEQAS) for Haematology, Watford, UK

Rachel Marrington, Birmingham Quality (UK NEQAS), Part of University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. <https://orcid.org/0000-0003-1045-8456>

Andrés Aburto Almonacid, Sección Hematología e Inmunoematología, Departamento Laboratorio Biomédico, Instituto de Salud Pública de Chile, Santiago, Chile

Stéphanie Albarède, Centre Toulousain Pour le Contrôle de Qualité en Biologie Clinique (CTCB), Toulouse, France

Tony Badrick, Royal College of Pathologists of Australasia Quality Assurance Program (RCPAQAP), Sydney, Australia. <https://orcid.org/0000-0003-4846-9134>

David Bullock, Former Director, Birmingham Quality, Former President, UK NEQAS, London, UK

Christa M. Cobbaert, Director of the Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Centre, Chair of the IFCC Scientific Division EC and Chair of the EFLM Task Force on European Regulatory Affairs, Leiden, The Netherlands

Wim Coucke, Sciensano, Quality of Laboratories, Brussels, Belgium. <https://orcid.org/0000-0002-4290-4628>

Vincent Delatour, Laboratoire National de Métrologie et d'Essais (LNE), Paris, France

Ana Paula Faria and Armandina Miranda, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal

Wolf-Jochen Geilenkeuser, Former, Reference Institute for Bioanalytics, Bonn, Germany

Andrea Griesmacher, Austrian Association for Quality Assurance and Standardization of Medical and Diagnostic Tests (ÖQUASTA), Vienna, Austria; and Central Institute of Clinical and Chemical Laboratory Diagnostics, University Hospital of Innsbruck, Innsbruck, Austria

Jim F. Huggett, National Measurement Laboratory, LGC, Teddington, UK; and School of Biosciences and Medicine, Faculty of Health & Medical Sciences, University of Surrey, Guildford, UK

Viktoriia Ianovska, NGO AQALM, Kyiv, Ukraine

Martin Kammel, INSTAND e.V. Society for Promoting Quality Assurance in Medical Laboratories, Düsseldorf, Germany; and GBD Gesellschaft für Biotechnologische Diagnostik mbH, Berlin, Germany

Anja Kessler, Reference Institute for Bioanalytics, Bonn, Germany

Günther F. Körmöczi, Austrian Association for Quality Assurance and Standardization of Medical and Diagnostic Tests (ÖQUASTA), Vienna, Austria; and Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria

Piet Meijer, ECAT Foundation, Voorschoten, The Netherlands. <https://orcid.org/0000-0003-4899-3294>

Dina Patel, UK National External Quality Assessment Scheme (UK NEQAS) Immunology, Immunochemistry & Allergy (IIA), Sheffield, UK

Paola Pezzati, SOD Sicurezza e Qualità AOU Careggi Firenze, Firenze, Italy

Sverre Sandberg, The Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Bergen, Norway

Harald Schennach, Tirol Kliniken GmbH, Zentralinstitut für Bluttransfusion und Immunologische Abteilung (ZIB), Innsbruck, Austria

Christian R. Schweiger, Clinical Institute of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

has been determined using reference measurement procedures (RMPs), EQA data contributes to the verification of metrological traceability of assays as part of the post-market surveillance of *in vitro* diagnostic (IVD) medical devices (IVD-MDs). More broadly, the scientific and medical communities use EQA data to demonstrate that medical laboratory examination procedures are fit for clinical purposes, to evaluate common reference intervals, and inclusion of data in clinical databases. Scientific groups, the IVD industry, reference laboratories and National Metrology Institutes can work with EQA providers to identify measurands, which should urgently be supported by the development of reference materials or methods. The ability of health systems to respond effectively to fast-evolving medical challenges, such as the Coronavirus Disease-19 (COVID-19) pandemic, is reliant on EQA to demonstrate confidence in the performance of new laboratory methods and testing services. EQA providers are uniquely positioned to assess the performance of IVD-MDs in addition to individual laboratories and testing sites. Although the primary focus of EQA providers remains the improvement of the performance of individual laboratories, there are many stakeholders who benefit from EQA performance data.

Keywords: external quality assessment (EQA); proficiency testing (PT); interlaboratory comparison; stakeholders

Introduction

This is Part V of a five-part series of articles describing principles, practices and benefits of External Quality Assessment (EQA) of the clinical laboratory. Part I describes the historical, legal, and ethical background of EQA and the properties of individual programs [1]. Part II deals with crucial properties of EQA cycles [2]. Part III is focused on the characteristics of EQA samples [3]. Part IV summarizes the benefits for participant laboratories [4], and Part V addresses the broad benefits of EQA for stakeholders other than participants.

Since the first survey on the assessment of accuracy of several measurands in medical laboratories in 1947 [5], the

practice of EQA has become established as an essential component of quality management. The primary aim of EQA is to focus on the laboratory's analytical performance compared to its peers or a trueness/equivalence based reference system [6]. However, as EQA providers collect and analyze data from many individual laboratories and can therefore provide a neutral "bird's-eye" view of the analytical performance of different examination methods and IVD-MDs, they can present a valuable contribution to reports on the performance of IVD-MDs under validation or evaluation conditions [7]. The list of examples is long, and EQA providers must meet the challenge of managing the sometimes contradictory expectations of different stakeholders (Table 1).

Stakeholders that benefit from EQA results and the services of their providers

Patients, clinicians and other users of laboratory services

The major stakeholders of the laboratory are patients and clinicians as their medical representatives, and an important question is, therefore, how they benefit from EQA. Medical laboratory testing can have a major impact on patient management concerning the diagnosis of a disease and monitoring of treatment [8]. However, published evidence that participation in an EQA program results in improved patient care and safety is limited [9–18]. Implementation of quality management systems based on ISO 15189 and ISO 9001 [15], involving participation in EQA and striving for continuous improvement of services, provides a solid foundation for quality in the laboratory and enhances patient safety. Another study demonstrated that about 70 % of laboratory errors impact on the diagnosis of patients [10]. Although patients are usually not aware of this, EQA and the

Karin Schwenoha, QMD Services, Vienna, Austria

Michael Spannagl, INSTAND e.V. Society for Promoting Quality Assurance in Medical Laboratories, Düsseldorf, Germany

Heungsup Sung, Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, South Korea

Marc Thelen, Foundation for Quality Assessment in laboratory medicine (SKML), Nijmegen, The Netherlands; and Department of Laboratory Medicine, Radboud Medical Center, Nijmegen, The Netherlands. <https://orcid.org/0000-0003-1771-669X>

Cas Weykamp, MCA Laboratory, Queen Beatrix Hospital, Winterswijk, The Netherlands

Heinz Zeichhardt, INSTAND e.V. Society for Promoting Quality Assurance in Medical Laboratories, Düsseldorf, Germany; and IQVD GmbH, Institut für Qualitätssicherung in der Virusdiagnostik, Berlin, Germany

Veronica Restelli and Lucy A. Perrone, Canadian Microbiology Proficiency Testing Program (CMPT), Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. <https://orcid.org/0000-0003-2185-688X> (L.A. Perrone)

Table 1: Benefits of EQA data and EQA providers' services for stakeholders other than participants.

Category: Stakeholders	Further use of samples for internal technical activities	Performance data			
		Of individual examination procedures/IVD-MDs	Comparison between methods	Assessment results	
	EQA providers services, programs and cycles	Assessment outcome	Of individual participants	User competence monitoring and development	
Patients and clinicians	Advance development and effective utilization of precision diagnostics.	Ensure diagnostic tests are safe, clinically effective, and appropriate for clinical purposes at relevant clinical decision limits	Evaluation of the extent of harmonization between examination procedures	Laboratory results with monitored accuracy	
	Publications presenting and interpreting EQA data	Performance assessment of IVD-MDs in routine use for post market surveillance purposes	Extent of harmonization between methods	Indications of technical issues	
IVD manufacturers	Examinations of the EQA material by the IVD manufacturer can be helpful in root cause analysis after laboratories failed in an EQA cycle.	Identification of tests with suboptimal performance (unsafe, ineffective) Comparison with performance of market companions			
		Identification of measurands needing harmonization			
Scientific community	Publications presenting and interpreting EQA data	Fitness for purpose at relevant clinical decision limits	Extent of harmonization between methods		
	Education	Detection of tests with suboptimal performance (unsafe, ineffective)			
Regulators	Support in the creation of clinical guidelines	Identification of measurands needing harmonization			
	Expertise on metrological traceability	Evaluation of metrological traceability and equivalence of measurement procedures			
Notified bodies	Maintain databases of performance data	Performance assessment of devices in routine use for post market surveillance purposes	Extent of harmonization between methods	Monitoring the meeting of analytical goals ^a	
	Notification about the abnormalities of the performance of individual IVDs	Detection of tests with suboptimal performance			
Regulators	Publications presenting and interpreting EQA data	Performance assessment of devices in routine use for post market surveillance purposes			
		Detection of tests with suboptimal performance			
Notified bodies	Publications presenting and interpreting EQA data	Long term monitoring of performance of individual tests			
		Recognizing major operational challenges that impact the reliability of results			

Table 1: (continued)

Category: Stakeholders	Further use of samples for internal technical activities	Performance data			
		Of individual examination procedures/IVD-MDs	Of individual participants	User competence monitoring and development	
	EQA providers services, pro- grams and cycles	Assessment outcome	Comparison between methods	Assessment results	
Accreditation bodies	Dialogue between EQA providers and accreditation bodies so that laboratories may meet expectations of ISO 15189:2022 at accreditation audits	Verification of stable performance of validated laboratory-developed tests		Third-party assessment of analytical performance of a laboratory	Part of the proof of competence of individual employees EQA results as the content of internal training measures
National health organisations and policy makers	Publications presenting and interpreting EQA data	Show the variability of values obtained by multiple identical and different test systems and thereby inversely show the extent of harmonization of measure- ment results for a measurand	Extent of harmonization between methods Performance data of different health technol- ogies Effectiveness data by comparing laboratory assays for health technology assessments	Individual monitoring of the members of groups that are authorized to carry out analytical procedures during pandemics	
Public health authorities	Publications presenting and interpreting EQA data on overall analytical performance to under- pin reliability of epidemiological data	Support in decision-making about the approval of test systems and operator groups other than medical laboratories for infection diagnostics Monitoring reliability of laboratory data serving as basis for epidemiological data	Extent of harmonization between methods		
EQA networks	Information exchange Publications presenting and interpreting EQA data Get together users, experts, public health authorities Organizing super challenges to collect EQA data from larger groups of participants and devices Joint procurement of materials for economic reasons	Monitoring the effectiveness of harmonization and standardization activities	Extent of harmonization between methods		

^aWhere applicable. EQA data and providers' services offer benefit for participants as well as for other stakeholders; depending on the stakeholder, the benefit concerns six areas (EQA providers' services; further use of samples for internal technical activities; assessment outcome of individual test systems; for the purpose of comparing different test systems; assessment of results of individual participants; user competence management) that offer varying extent of benefits for them (high; moderate; low/none); >1 items per category or one extraordinary important item=high benefit; one moderately important item per category=moderate benefit as shown in Figure 1.

support of participant laboratories by its providers, contribute to the enhancement of patient safety as part of a quality management system that aims to minimize the risk of the release of erroneous results [16, 17]. Performance assessment in EQA with samples at concentrations used in guidelines to distinguish between different clinical decisions, can identify whether the performance of laboratories meets the assumptions made in such guidelines. A recent study used EQA based performance data to demonstrate the difference in the ability of laboratories to comply with the guidelines of the European Society for Cardiology on the assessment of non-ST-elevation myocardial infarctions (NSTEMI). In that study, misclassification between rule in and rule out was 0.0001 % for laboratories passing EQA performance and 2 % for those who did not, where the guideline allows for 1 % misclassification [18]. Such studies make clinicians aware of the relevance of laboratory performance for patient safety and the relevance of EQA to be the safe keeper of this.

Another group of users of laboratory services are institutions that do not require laboratory results directly for the treatment of individual patients, but indirectly, such as the pharmaceutical industry in the context of clinical studies, or users of blood products and derivatives who expect reliability of results and compliance of examination procedures with the requirements for immunohaematology and infectivity testing with sufficient competence and using appropriate methods. They can accept confirmation of the responsible laboratory's successful participation in EQA as proof of general testing competence, even without being technically familiar with the subject of the laboratory's activities.

EQA providers should select samples that provide clinically relevant challenges, mimic patient specimens as far as practicable, i.e. which are commutable [19]. Several studies have demonstrated the educational value of including clinical case scenarios in EQA or interlaboratory studies [20, 21] to support patient awareness of potential problems, the appropriate interpretation of laboratory results, and the correct diagnosis. Therefore, EQA providers benefit patients by focusing on all phases of the diagnostic process and not solely on analytical performance.

Manufacturers of IVD systems

EQA programs can reveal the relative performance of different examination procedures and IVD-MDs,

contributing thereby to post-market surveillance of IVDs as required by European Standard (EN) 14136:2004 and the IVDR [22, 23]. EQA data reflects real-time laboratory performance with different IVD-MDs and can often include results from multiple laboratories, instruments, operators and reagent lots. Data from validation or evaluation studies, on the other hand, refer to specific settings to test and present the performance of an IVD-MD at a specific time. These two types of performance data complement each other and present far more aspects than just one type alone.

The quality and reliability of EQA data in this regard depend on the completeness of the information provided by participants about the IVD-MD used and the commutability of the EQA samples. Laboratories are responsible for providing detailed information to their EQA provider about the examination procedure used and to declare any deviation from the protocol of the IVD manufacturer so that they can be classified as using a laboratory-developed test (LDT) and be excluded from data used for post-market surveillance. The need for commutable sample material to be used in EQA is to ensure that observed differences between examination procedures are not the result of a property of the sample material but relate to the examination itself, for example, lack of accuracy and/or selectivity for the measurand. Therefore, the commutability of EQA samples should be examined wherever possible [24].

The scientific community

Medical laboratory science and research

EQA providers play a prominent role in the scientific and medical laboratory community, supporting the following scientific and medical objectives:

- (1) Ensure diagnostic tests are appropriate for clinical purposes.

Medical tests should fulfill clinical needs, deliver actionable results and have a defined test purpose in the clinical care pathway. In the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) landmark paper on test evaluation [25], the five key elements of test evaluation (analytical performance, clinical performance, clinical effectiveness, cost-effectiveness and the broader impact) are structured in a cog wheel framework around the clinical care pathway, which implies that the clinical utility of a test

is dependent on its analytical performance. As evidence-based clinical guidelines evolve, the analytical performance of tests should be aligned to ensure that the required clinical performance specifications can be met [26]. Fitness for clinical purpose becomes challenging when tests with lower clinical decision limits and higher analytical sensitivity are needed. EQA programs should ideally be able to evaluate performance at critical decision-making limits, e.g., highly sensitive cardiac troponin in the 0/1 h NSTEMI algorithms for detecting acute coronary syndrome [18, 27–29]. For albumin, the selectivity based interference of Bromocresol Green examination methods renders them unsafe for decisions on protein loss in patients with nephrotic syndrome, which can be demonstrated in EQA performance when samples reflect the composition in real life patients [30].

- (2) Ensure diagnostic tests are safe, clinically effective, and do not cause harm to patients.

EQA program designs should enable the detection of suboptimal examination methods and identify underperforming IVD manufacturers and/or IVD-MDs. The selectivity of the examination procedure for the measurand, the result accuracy (encompassing both trueness and precision), and the degree of standardization or harmonization between examination methods are all determinants of test fitness for purpose and support the universal application of clinical guidelines and decision limits. Ideally, pre-examination, examination and post-examination aspects of the total testing process should be assessed, to estimate whether the combined measurement uncertainties are within the allowable limits, e.g., prolactin immunoassays that do not differentiate an insignificant macroprolactinemia from a real hyperprolactinemia in case of a prolactinoma, in this case offline preparation, for example, by polyethylene glycol precipitation, may be required. The impact of this will need to be taken into consideration [31].

- (3) Advance development and effective utilization of precision diagnostics.

EQA providers have a role in the monitoring and evaluation of test quality of all IVDs, as long as the statistical sample size is adequately met for comparison's sake. In this era of precision medicine, all IVD users should participate in EQA, especially institutions that develop and utilize LDTs for clinical care. As classified by the U.S. Food and Drug Administration (US FDA) and the European IVDR, LDTs are IVD-MDs that are designed, manufactured and used within a single clinical laboratory that meets certain requirements [32]. A specific example of this is for molecular oncology applications, where EQA providers need to manufacture carefully molecularly characterized samples (e.g. through (glyco-)proteotyping of specific dysfunctional protein proteoforms) that allow a clear

molecular definition of a patient's health baseline and disease states, and which will enable effective patient management.

Other examples include the proteotyping of specific glycoproteoforms of prostate-specific antigen (PSA) that distinguish benign prostate hypertrophy from malignant prostate cancer [33], and the proteotyping of antithrombin to improve the detection of antithrombin deficiency [34, 35]. For this type of advanced testing and quality assurance, EQA providers should consider direct collaboration with expert laboratories to design EQA programs that best evaluate these specialized molecular tests. EQA participation and collaboration support innovative precision medicine by providing objective testing data and preventing underdiagnosis and undertreatment of patients.

The US FDA issued a Final Rule on May 6, 2024, that will, over the next four years, radically alter the landscape for LDTs and “correct the imbalance” between IVDs marketed outside a laboratory and those IVDs manufactured by a laboratory [36]. Regulatory compliance expectations will be introduced for certain types of IVDs offered as LDTs in five stages. Each stage adds additional compliance expectations, with which clinical laboratories using LDTs will need to comply. These requirements are regulatory tools already applied in enforcement against traditional IVD manufacturers: adverse event reporting, establishment registration and device listing, labeling standards, investigational use requirements, and, as new IVDs enter the market or are significantly modified, CGMPs and premarket review [37, 38].

Scientific and professional associations

Professional and scientific associations may look to EQA programs that are able to evaluate metrological traceability and equivalence of examination procedures to support pan-laboratory activities [39]. EQA programs provide evidence that can be used by clinical guideline developers and clinical groups to show that results from different laboratories, examination methods, or IVD-MDs provide equivalent results. Without this assurance, clinicians cannot interpret results from different laboratories using common approaches. For example, EQA with commutable materials with reference method target values provides direct evidence about metrological traceability within allowable limits of measurement uncertainty (MU) of examination methods. Suppose methods are demonstrated to have traceability within allowable MU. In that case, the results from these examination methods can be combined in databases or can be interpreted using common decision criteria. That is, the results are metrologically equivalent. Specifically, under these circumstances, results from different methods can be used:

- Common reference intervals. Common reference intervals allow safer and easier interpretation of patient

results from different laboratories. However they can only be used if the results from different examination methods are demonstrated to be equivalent [40].

- Combined data into clinical databases. Results from different examination methods must be shown to be equivalent before they can be combined into a common database. Clinical databases are becoming more common and are driving improved health outcomes and reduced costs by avoiding unnecessary repeat testing.
- Clinical guidelines. Guidelines are developed with a decision level for a rule-in or rule-out assessment of a disease (e.g. anemia, diabetes). For these decision levels to be applicable across different examination methods, they must report equivalent results.

Particularly worth mentioning within the scientific community are groups working on the improvement of harmonization and metrological traceability of medical laboratory results. They may identify routes by which results' harmonization and/or accuracy should be improved, for which reference methods and/or reference materials are needed, and in what format to underpin traceability. This is of particular importance, given the high number of measurands for which reference materials and/or RMPs, which, when used together to provide traceability across a network of reference laboratories, are described as reference measurement systems [41] are lacking. The prioritization of the measurands for which reference measurement systems are the most urgently needed is essential. This is important in areas where reference systems are being developed to support more complex measurands, such as in bioanalytical testing using proteins ranging from smaller biomarkers (e.g., procalcitonin) to more complex protein structures such as antibodies [42] or nucleic acids, including DNA [43] and RNA [44] analytical techniques. Activities and achievements of the initiative for Harmonization of measurands in Laboratory Medicine through data Aggregation (HALMA) [45], the International Consortium for Harmonization of Clinical Laboratory Results (ICHCLR) [46], the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) [47–49], the Joint Committee for Traceability in Laboratory Medicine (JCTLM) [50, 51], the international meeting forum “Standardization of Genome Amplification Technologies” (SoGAT) [52], and the European Metrology Network in Laboratory Medicine (EMN TraceLab) [43, 53, 54] are summarized in Table 2. EQA can serve as a mechanism to check the success of harmonization initiatives but can also provide samples and data to initiate harmonization, as shown in recent international collaboration using EQA programs from six different providers to study and improve the harmonization of tumor markers [55].

Of course, there are also scientific and professional associations that deal with qualitative tests and for whom metrological traceability of results has limited relevance. In specialized laboratory networks linking patients with complex biological products (like transfusion or transplantation), professional organizations provide mandatory EQA to standardize and secure crossmatch and allocation procedures. The Eurotransplant (ETRL) network operating in Austria, Belgium, Croatia, Germany, Hungary, Luxembourg, the Netherlands and Slovenia, requires for participation in this network that member states fulfill as a prerequisite, among others, Human Leukocyte Antigen (HLA)-typing and cross-matching by a European Federation for Immunogenetics (EFI) accredited laboratory [56]. EFI standards require participation in an EQA program that covers all the accredited laboratory applications (i.e. HLA typing, antibody screening and identification, cross-matching, etc.) and all techniques used to produce a final result. EFI standards also have explicit requirements concerning the EQA procedure itself, the minimum number of samples circulated per year and the reporting of EQA results. The EQA program used for most applications is that of the ETRL reference laboratory network, which has provided regular EQA for decades. Correct and reproducible identification of HLA antigens and antibodies within the network of HLA labs linked to the regional transplant centers finally allowed virtual crossmatching as a standard procedure in organ allocation within ETRL since 2024.

EQA data as an investigation and monitoring tool

Analysis of EQA results allows for a more generalized view of success factors for good laboratory performance. The impact of operating quality management systems, the degree of specialization of laboratories, national regulatory and economic conditions, and EQA provider's services using EQA outcomes were investigated using immunohaematology EQA data. Laboratories with ISO 9001 certification or accreditation showed only about half the number of errors in EQA results in comparison to laboratories without. Also the degree of specialization of participating laboratories is reflected in EQA performance, with significantly better results of transfusion services compared to hospital or independent laboratories [15]. Based on a large international study, legally required quality standards or national economic conditions seemed not to correlate with error rates in EQA but rather the support provided by the EQA provider in case of incorrect results [17]. These two articles are examples that show that performance in EQA can be determined by external influences. Still also – and this is the topic here – that EQA performance can be used as a means of identifying the effects of certain influences on the laboratory.

Table 2: Groups working on improvement of harmonization and metrological traceability of medical laboratory results.

Group	Activities and achievements
HALMA – HARmonization of measurands in Laboratory Medicine through data Aggregation	ICHCLR and the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM) have joined forces for an initiative to combine results from various EQA providers which may provide a powerful tool to monitor harmonization of examination procedures in the medical laboratory [44].
ICHCLR – International Consortium for Harmonization of Clinical Laboratory Results	ICHCLR provides a centralized process to organize global efforts to achieve harmonization of clinical laboratory test results and presents a list of the harmonization and standardization status of a number of measurands [45].
IFCC – International Federation of Clinical Chemistry and Laboratory Medicine	The IFCC Scientific Division structurally manages for decades the establishment and adoption of reference services by ~25 IFCC working groups [47] and committees [46]; among them is the IFCC Committee for Traceability in Laboratory Medicine (C-TLM) [48] that organizes an interlaboratory comparison program for reference laboratories.
JCTLM – Joint Committee for Traceability in Laboratory Medicine	JCTLM was established through a declaration of cooperation between the International Bureau of Weights and Measures (BIPM), the IFCC, and the International Laboratory Accreditation Cooperation (ILAC). The aim of this consortium is to support worldwide equivalence and comparability of measurement results in laboratory medicine, for the purpose of improving health care [49]. The main output of the JCTLM is the global database of higher order reference materials; reference measurement methods/procedures; and reference measurement services [50].
SoGAT – international meeting forum “Standardisation of Genome Amplification Technologies”	With a focus on infectious diseases, this forum of scientific and clinical experts, IVD manufacturers, regulatory laboratories and EQA providers identifies and prioritizes the needs of the diagnostic community for higher order reference materials established by the World Health Organisation Expert Committee for Biological Standardisation [51].
TraceLabMed – National Metrology Institutes, recently organized in the European Metrology Network “TraceLabMed”	To fulfill their legal mandate, National Metrology Institutes (NMI) develop RMPs and are also responsible for developing advances in metrology at an international level. They can respond to the needs of EQA providers and their stakeholders. Examples in bioanalysis include the development of reference measurement procedures for protein [52] and nucleic acid analysis [42, 53] to improve standardization by complementing material standards and providing novel routes for traceability.

Groups publishing on scientific EQA projects

In 2023, a review of the current literature on interlaboratory comparison, EQA, and proficiency testing (PT) by members of the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM) Scientific Committee showed inconsistency on the items reported in publications on such results and omission of essential details for EQA. EQALM has, therefore, decided to prepare guidelines on items that are considered essential (recommended) for inclusion in papers reporting interlaboratory comparison studies. These comprise the description of the activity, information on items (samples) used, information and instructions provided to the participants, information on participant entities and on participating examination procedures and IVD-MDs, way(s) of submission of results, procedures for evaluation and assessment of results, reports to participants (and other interested parties), findings from the study, limitations of the study, and impact of the outcome of the activity [57].

Regulatory authorities

Accuracy, timeliness and reliability of laboratory results are of crucial importance in healthcare. Consequently, many jurisdictions mandate a minimum performance that laboratories must achieve to practice. This usually involves accreditation to a standard such as ISO 15189 and local regulations to protect the public from harm and ensure consistency in laboratory practice. The local regulation may dictate performance criteria, frequency, number of failures allowed before a practice license is in jeopardy, and identification of measurands that require EQA and/or authorized EQA providers. Regulatory Authorities of European Union (EU) and European Free Trade Association (EFTA) member states and other European countries are listed elsewhere [58]. In some countries and for certain measurands, enrolment in appointed EQA programs may be required. This is of particular importance when laboratory results are used in legal cases and decisions, like ethanol tests are used to judge

on driving ability and Carbohydrate-deficient transferrin (CDT) tests are used to decide on successful alcohol abstinence to gain back a driver's license after withdrawal [59].

Where appropriate, EQA providers ensure that regulators are informed of poorly performing test systems that could result in patient harm. Examples are American Clinical Laboratory Improvement Amendments (CLIA), and the Guidelines of the German Federal Medical Society for the Quality Assurance of Laboratory Medical Examinations (RiliBÄK) [60, 61]. Failure of a test system to meet the performance standard can result in the suspension of approval until the expected performance is achieved again.

There can, however, be unintended consequences from this approach. A regulatory program typically includes a set number of samples for all measurands specified in the regulations. Consequently, there is less flexibility, and the concentrations do not challenge the limits of the measuring interval or if examination procedures may be influenced by interfering substances. Also, these EQA samples may be treated differently to patient specimens to ensure acceptable performance, and the performance criteria usually can be met by nearly all laboratories [62].

Notified bodies for IVDR compliance

Notified bodies are legal entities established under the national laws of EU member states, which fulfill the criteria of Annex VII of IVD-Regulation 746/2017 [23]. They are entitled to authorize manufacturers to use the Conformité Européenne (CE) mark for IVD products after a thorough conformity assessment. This assessment process accompanies the products throughout their whole life cycle. They must act independently and impartially. They must not have any commercial relations with the manufacturer of the assessed products except for the agreement on the conformity assessment. Notified bodies are not allowed to provide consultancy services. They have to make sure that all their personnel involved in an assessment are completely independent of the manufacturer and are not part of the design, manufacture, marketing or installation of the products assessed at any time. Notified bodies are supervised by national authorities of the member state and by the EU Commission.

The relevance of EQA programs for regulatory purposes is described in the article 11.2 of the IVD-Directive 98/79 on IVD-MDs (IVDD) [63]. Consequently, the European Commission mandated the new standard, ISO/IEC 17043:2023 Conformity Assessment – General Requirements for proficiency testing, which was harmonized with IVDD. As parts of the supervision of IVDs have been transferred to notified bodies by IVDR, these institutions will have considerable interest in the results of EQA-programs, because they give important information about the performance of an IVD in the field, as required by

Annex XIII, 5.2 of the IVDR [23]. The benefit of EQA results is that they were obtained by IVD-MDs in routine use but not under special conditions focused on performance assessment in validation or evaluation settings. IVDR requires manufacturers to practice life cycle management for their products by periodically doing surveys of the relevant scientific literature and systematically searching for information about the performance of the product in the market. Depending on the risk classification of the product, manufacturers will have to deliver safety reports, for example summary of safety and performance (see article 29 IVDR) or periodic safety update report (PSUR, see article 81 IVDR) to their notified body. These two reports have to include, among other things, summaries of the performance evaluation, residual risks and benefit-risk determination. Results of EQA programs are an excellent means to get summarized information about IVDs based on independent samples, tailored to mimic patient specimens and analyzed in multiple laboratory settings. Due to the requirement of the IVDR to have the performance of high-risk products checked in reference laboratories, cooperation between EQA providers and notified bodies is desirable.

Also, since IVDR requires batch releases on an ongoing basis for high-risk IVD-MDs (Class D), it would be of interest to both manufacturers and notified bodies to consider whether some EQA programs could be used for this process. For the recently described method of evaluating the EQA variability of assays for POCT, please refer to Section 4.2 of the IVDR on Manufacturers of IVD systems [23]. The variation of different test systems in EQA programs can be put into context and provide the notified body with information on the variability of individual measured values for the same samples, which should be as low as possible in POCT systems. A limitation of this tool is that EQA data are only available for post-market surveillance, but not for the initial assessment for the approval of devices.

Accreditation bodies

Regarding ISO 15189:2022

The ISO standard 15189:2022 requires medical laboratories to participate in an interlaboratory comparison for each examination procedure employed in the laboratory. Some assessors for accreditation bodies, including laboratories, may consider that such EQA participation is an end in itself, without consideration of the suitability of the interlaboratory comparison for the laboratory's purpose; however, this enrollment should not be the end of the quality partnership. ISO 15189:2022 focuses on the purpose of EQA participation as a tool to verify that the performance of an examination procedure remains as adequate as when accepted during validation or verification. To meet that goal,

an EQA program needs to be suitable. In reality, only an EQA using commutable samples, values assigned with reference measurement procedures [64], is suitable for the full verification of metrological traceability. It is an advantage if the report has tolerance limits based on medical need for the measurand and the report provides relevant information for the guidance of corrective action.

However, notwithstanding value assignment by a reference measurement procedure, EQAs may still be used to verify a between-method harmonization process by examining equivalence of results. If sample materials are not commutable, this is limited to method-specific performance evaluation. EQA providers accreditation to ISO/IEC 17043:2023 alone does not make a program suitable for EQA purposes. EQA providers should educate accreditation bodies and their assessors in evaluating EQA participation from this perspective rather than check-listing that the laboratory participates in an ISO/IEC 17043:2023-accredited program and performs corrective action where performance is outside limits. An active dialogue between EQA providers and accreditation bodies should be encouraged.

Regarding ISO 17025:2017

ISO 15189:2022 was developed as a medical field specific version of ISO 17025:2017 [65] to serve the specific needs and challenges in medical laboratories. Regarding EQA, these ISO 15189 aspects relate to specific performance specifications for specific medical indications, which could differ between different indications for the same measurand.

The existence of ISO 15189 as a medical version of the ISO 17025 does not mean ISO 17025 is irrelevant for the medical field. Since ISO 17025 accreditation is required for calibration activities, it is a requirement for reference laboratory services in ISO 15195:2018 [66] and providers of reference materials in ISO 15194:2009 [67], in the medical field. In order to meet the standard's requirement for interlaboratory comparisons, parties working together in the JCTLM have decided to require a specific EQA service specifically set up to cover the needs for such services [68]. In contrast to routine laboratories, the identity of the participating laboratories is disclosed. This allows medical EQA providers serving ISO 15189 accredited laboratories make use of the services of laboratories participating in RELA for the assignment of target values of their EQAs where possible and relevant [4, 68].

Regarding ISO 17043:2023

In many aspects, EQA providers serving medical laboratories are comparable to EQA providers in other fields. For all these identical aspects, all elements in ISO 17043:2023

have to be covered to ensure an EQA service with a low risk of malperformance. However, as illustrated in the previous paragraphs, the field of laboratory medicine has specific aspects that add challenges to organizing a suitable EQA for this sector. There are at least two elements that deserve to be mentioned here. First, the definition of the measurand is not clear or even univocal in many cases as different proteoforms of the same measurand co-exist, other techniques have different specificity for those proteoforms. Secondly, although (lack of) commutability could in theory complicate any laboratory discipline, in practice, especially the field of laboratory medicine, seems to suffer from its impact possibly related to the complicated, overcrowded measurement matrices of human body fluids. When national accreditation bodies assess EQA organizations for their ISO 17043 accreditation, their assessors become aware of these challenges in the dialogue between assessor and assessee. Equipped with such information and insights, assessors will bring such knowledge to their accreditation bodies which can apply these insights in the training of their assessors for ISO 15189 accreditation.

National health organizations and policy makers

Health Technology Assessment (HTA) is a systematic, evidence-based process that examines and compares both clinical and non-clinical aspects of (new or existing) health technologies [69–71]. HTA acts as a link between science and politics by compiling findings from research or generating findings themselves and “translating” them so that they support decision-makers. The idea behind this is to lead to a more efficient use of resources in the healthcare sector and to ensure the highest level of security in the healthcare system. Although laboratory results may be decisive for the performance of health technologies, quality aspects seem to have not yet been fully recognized by HTA [72]. It should be noted that not all examination methods and measurands are harmonized, and therefore, “measuring” and “examining” do not necessarily mean obtaining reliable and interchangeable results regardless of the IVD-MD used. EQA results show the variability of results obtained by multiple identical and different IVD-MDs and thereby inversely show the extent of harmonization of results for a measurand [73]. In particular, the role of EQA as a unique comparison of examination procedures and IVD-MDs under routine conditions should be considered. In addition to the variability of quantitative examination results, EQA programs also compare rates of true positive and false negative results and, thus, the performance of IVD-MDs for pathogen detection used in the field [74–76].

Public health authorities during public health emergencies

Quality laboratory and diagnostic data is critical in a public health emergency. Key epidemiological data like case counts and disease incidence are based on aggregated individual test results, and thus, the accuracy of these indicators depends on the performance of assays used in testing facilities, more precisely on their true positives and false negatives rates. The important role of EQA providers and their programs for public health authorities was clearly demonstrated during COVID-19 pandemic from 2020 to 2023. In this global health emergency, loosened national and international regulations allowed numerous new examination procedures and IVD-MDs to be brought onto the market within a short period of time without extensive validation. New manufacturers appeared just as quickly as new distributors and new diagnostic test facilities started operating for the first time where previously they had no experience in human medicine. EQA programs for SARS-CoV-2 pathogen detection were deployed early in the COVID-19 pandemic so that participants could obtain information about the performance of their examination procedures [77–80]. An early provision of EQA is definitely supported by existing experience with the establishment of EQA programs for the detection of emerging pathogens [79]. In order to provide laboratories with feedback on the performance of their analysis as early as possible, revealing the EQA results quickly after or even during the ongoing cycle was helpful [81]. In some countries, successful participation in EQA programs was required for the qualification of laboratories to carry out SARS-CoV-2 pathogen detection [82]. The results of the earliest cycles already showed that the C_q values reported by different examination procedures for the same samples were highly variable and therefore, could not be compared with each other and cannot be used as a reliable indicator of the virus load [77, 78, 83–86]. In later cycles, the impact of converting C_q values into an international unit system on the harmonization of results for SARS-CoV-2 quantification was examined and reported to be beneficial [87]. Furthermore, significant limitations of rapid antigen tests and the impact of testers' experience and training were highlighted [74, 75, 88], just as the disharmonic anti-SARS-CoV-2 antibody quantification by different examination procedures [89], the low sensitivity inherent in some SARS-CoV-2 pathogen detection assays [90], and the diluting effect of sample pooling procedures [91]. In addition, EQA providers used their expertise and their unique central position to provide numerous laboratories with national reference materials with which they could relate copy numbers in the

samples to the C_q values of their analysis systems [44]; they clarified the nonscientific public misinterpretation of the prevalence of SARS-CoV-2 infections reported as being based on false positive test results [92]; they pointed out that the mention of test performance, in particular the rate of incorrect negative test results, was missing in an otherwise comprehensive article about the lessons for the future from the COVID-19 pandemic [93, 94]; they showed that the overall performance of SARS-CoV-2 virus genome detection did not improve over the time of the pandemic; they pointed out the danger of incorrectly interpreting negative test results as ruling out an infection [95]; and based on experiences from the COVID-19 pandemic, recommendations were made to EQA providers for future epidemics [96] (Table 3).

Some particular examples of notable activities and findings of EQA providers and their programs are presented in Supplement 1.

Table 3: Recommendations to EQA providers for future epidemics.

-
- (1) Seek early arrangements with public health authorities so that in the case of an outbreak, epidemic, or pandemic:
 - All test facilities, ideally with each of their individual test systems, are obliged to participate in EQA
 - Test facility participation is verified
 - In return, participating in EQA should be free of charge for test facilities participating in public health-relevant analytics
 - Preventative actions after a failure in EQA are reviewed by experts
 - (2) Provide EQA programs early. EQA should be available as soon as testing begins
 - (3) Be flexible in designing and adapting EQA programs so that they best accompany the epidemic and the participating laboratories and test facilities; done in coordination with public health authorities
 - (4) Prepare programs and reports to regularly report on:
 - Types and numbers of registered examination procedures and IVD-MDs
 - Counts and categories of test facilities enrolled
 - Study time
 - Rates of false-positive and false-negative results, and analytical sensitivity of assays
 - Interassays and intratype variability
 - If applicable, proportion of test systems compliant with relevant recommendations
 - Sample specification in a commonly used unit
 - Reporting on these categories will support participants, public health authorities, other EQA providers, and the scientific community
 - (5) Make the summary report available shortly after the end of a cycle, or give participants immediate feedback on their results
 - (6) Immediately report suspicious or alarming findings to health authorities
 - (7) Take the role as a contact for non-EQA inquiries and a network partner seriously:
 - Use the central position to share up-to-date information with participants
 - Support participants standardizing their assays
 - (8) Support concerted campaigns and expert information exchange on EQA through participation
-

Adapted from [96].

EQA providers' networks

EQA providers are in close contact with all laboratories participating in their programs, although the extent of this contact depends upon the staff resources of the EQA provider. In a survey of EQALM in 2022, the majority of EQA providers stated that they regularly receive technical inquiries on a wide variety of topics about analytical issues and also that they have sufficient and competent staff available to be able to answer these inquiries satisfactorily (unpublished). This important service underlines the value of EQA providers who know local regulations and laboratory practices. EQA providers may partner with laboratories or countries to support the implementation of a comprehensive program of laboratory quality improvement, encompassing IQC, EQA, method harmonization and education, e.g., the Project of Laboratory Quality Improvement for Portuguese Speaking Countries (ProMeQuaLab) [97]. ProMeQuaLab began in 2015 and is coordinated by the National Health Institute of Portugal (INSA). It is a cooperation project that aims to improve the quality of medical laboratories within the scope of EQA and IQC based on education, training and the application of good laboratory practices in the proper diagnosis and treatment of patients.

Collaboration between EQA providers allows multi-functional opportunities. The ability to compare performance characteristics of individual examination procedures across multiple EQA provider programs provides confirmation of performance issues. A common criticism of EQA is that the EQA sample is “different” from patient specimens, and is, therefore, the cause of the performance issues observed by the EQA provider. Collaboration between EQA providers can confirm in commutable samples that method-related performance issues exist for the measurand and are not attributable to the EQA sample matrix. Such collaboration assists conversations with regulatory bodies and manufacturers and supports the prompt, effective resolution of analytical issues. The COMET project (Manufacturing of COMmutable calibrators and quality control materials for standardization and post-market surveillance of IVD tests) funded by the European Partnership in Metrology aims at addressing these challenges by evaluating commutability of a large number of EQA materials for key measurands. Identifying the most suitable matrices associated with high commutability levels and assigning reference method assigned values to EQA materials of proven commutability will pave the road towards enhanced post-market surveillance and make it possible to aggregate EQA data with confidence, which will support the development of the EQALM central database. The EQALM central database aims to

centralize EQA results from various EQA providers to answer questions that are hard to answer using data from a single EQA provider. The advantage of centralizing data from various EQA providers is that conclusions can be drawn from a multitude of EQA samples analyzed in a short time span on a global scale, and this helps to answer questions about post-market surveillance, performance assessment of examination procedures and harmonization between them.

Individual collaborative studies are supported by EQA providers circulating identical samples across multiple programs. An example is the INPUTS project of EQA organizers in Italy, the Netherlands, Portugal, the United Kingdom and Spain, in which the performance of 17 general chemistry measurands was investigated across countries and manufacturers [98]. A second project of the same group focused on the suitability of routine creatinine assays for clinical applications [99]. Another example is an international collaboration with EQA organizations from Australia, Germany and the UK, in which the same five samples were provided to the participating laboratories for quantitative examinations of the cytomegalovirus genome within a defined time window during the respective national EQA cycle [100].

Apart from *ad hoc* initiatives there can also be structural collaboration, e.g., EQA organizers in Australia, Belgium, France, Italy, Spain, and the Netherlands share a program on trace elements. Each organizer has too few participants but together they have a viable statistical basis, shared quality targets and a multilingual website for the submission of results and retrieval of reports [101, 102]. EQA organizations across Europe shared their experiences, initially through meetings of the Joint Commissions for Standardisation and later those convened by the Bureau Communautaire de Référence (BCR), leading to collaborations and international comparisons. A particular success story was for specific proteins, where UK-led comparisons demonstrated that inadequate calibration was the main source of variation, prompting the production and validation of a European Reference Material, CRM470 [103, 104]. A large-scale example is a collaborative project between the IFCC and 25 national EQA organizers in Europe, Asia and America on the determination of HbA_{1c} [105]. Once a year, two commutable samples, targeted by the IFCC network of reference laboratories, are manufactured in one site and shipped in bulk to the national EQA organizers for distribution to their participants. The IFCC network coordinator aggregates the results to provide overviews (a) per country, (b) per manufacturer, and (c) per country per manufacturer (Figure 2). The assessment of reported results in such “super challenges” remains with the individual EQA provider, who forwards the anonymized results for further evaluation to the study coordinator. The large and




Figure 1: Benefits of EQA data and their providers' services to stakeholders other than participants. EQA data and providers' services offer benefit for participants as well as for other stakeholders; depending on the stakeholder, the benefit concerns six areas (EQA providers' services; further use of samples for internal technical activities; assessment outcome of individual test systems; for the purpose of comparing different test systems; assessment of results of individual participants; user competence management) that offer varying extent of benefits for them (high; moderate; low/none); >1 items per category (Table 1) or one extraordinary important item=high benefit; one moderately important item per category=moderate benefit.




Figure 2: Overview of results of an EQA super-challenge including 3286 laboratories via 25 EQA providers. The Figure shows aggregations of the 3286 laboratories in the 2020 trial per country (A), per manufacturer (B) and per manufacturer per country (C) in the framework of the IFCC model for quality targets. The imprecision (between laboratory CV in %) is on the horizontal and the bias (difference from the target) on the vertical axis. The white, amber, gray and yellow triangles enclose areas for performances at a minimum, bronze, silver and gold level [104].




Figure 3: Laboratory total testing process, EQA programs, cycles and sample preparation, and benefits of EQA for participants and stakeholders other than participants. Relationship of the laboratory total testing process, EQA cycles including, the preparation of samples used in them, and EQA programs, and the benefits that EQA provides to participants and stakeholders other than participants.

international scale provides pressure to improve, when required. And it works: from year to year poor methods are removed from the market and replaced by improved systems. EurA1c demonstrates the power of collaboration between EQA organizers and might be a model for future development.

Conclusions

After the properties of EQA programs, cycles and samples used in them, the benefits of EQA data and their providers' services for stakeholders other than participants were presented in this part of the article series (Figure 3). EQA data and the services of EQA providers enable many stakeholders to receive unique, important, and meaningful data that can only be obtained by aggregation of results that numerous participating laboratories have determined with many of the same and different test systems in identical samples. EQA providers, laboratories, the diagnostics industry and all other stakeholders should work together to maximize efficacy.

Acknowledgments: The authors wish to express their gratitude to Anna Malikovskaia for her support with the management of the extensive bibliography of this five part paper

series, and Christian Hummer-Koppendorfer for the excellent graphical artwork.

Research ethics: Not applicable.

Informed consent: Not applicable.

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Use of Large Language Models, AI and Machine Learning Tools: None declared.

Conflict of interest: Heinz Zeichhardt declares that he was co-chairman of the Joint Diagnostic Council of the Deutsche Vereinigung zur Bekämpfung der Viruskrankheiten e.V. (DVV e.V.) and Gesellschaft für Virologie (GfV e.V.) and was Advisor for the INSTAND External Quality Assessment (EQA) schemes in virus diagnostics (until 2023). He is owner and managing director of IQVD GmbH – Institut für Qualitätssicherung in der Virusdiagnostik, Berlin, and was majority owner and managing director of GBD Gesellschaft für Biotechnologische Diagnostik mbH, Berlin (until 2022). He declares that he has no conflicts of interest with regard to the activities mentioned in relation to the publication. All other authors state no conflict of interest.

Research funding: None declared.

Data availability: Not applicable.

Statement: Points of view in this document are those of the authors and do not necessarily represent the official position of their affiliated organizations. Where certain commercial software, instruments, and materials are identified in order to specify experimental procedures as completely as possible, such identification does not imply recommendation or endorsement by the authors, nor does it imply that any of the materials, instruments, or equipment identified are necessarily the best available for the purpose.

References

- Buchta C, Marrington R, De la Salle B, Albarède S, Badrick T, Berghäll H, et al. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA), Part I – EQA in general and EQA programs in particular. *Clin Chem Lab Med*. <https://doi.org/10.1515/cclm-2024-1289>.
- Buchta C, De la Salle B, Marrington R, Aburto Almonacid A, Albarède S, Badrick T, et al. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA), Part II – EQA cycles. *Clin Chem Lab Med* 2024. <https://doi.org/10.1515/cclm-2024-1290>.
- Buchta C, Marrington R, De la Salle B, Albarède S, Albe X, Badrick T, et al. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA), Part III – EQA samples. *Clin Chem Lab Med* 2024. <https://doi.org/10.1515/cclm-2024-1291>.
- Buchta C, De la Salle B, Marrington R, Albarède S, Bardick T, Bietenbeck A, et al. Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA) Part IV – benefits for participant laboratories. *Clin Chem Lab Med* 2024. <https://doi.org/10.1515/cclm-2024-1292>.
- Belk WP, Sunderman FW. A survey of the accuracy of chemical analyses in clinical laboratories. *Am J Clin Pathol* 1947;17:853–61.
- Miller WG. The role of proficiency testing in achieving standardization and harmonization between laboratories. *Clin Biochem* 2009;42: 232–5.
- Buchta C, Müller MM, Griesmacher A. The importance of external quality assessment data in evaluating SARS-CoV-2 virus genome detection assays. *Lancet Microbe* 2022;3:e168.
- Horvath AR. From evidence to best practice in laboratory medicine. *Clin Biochem Rev* 2013;34:47–60.
- Allen LC. Role of a quality management system in improving patient safety – laboratory aspects. *Clin Biochem* 2013;46:1187–93.
- Miligy DA. Laboratory errors and patient safety. *Int J Health Care Qual Assur* 2015;28:2–10.
- Tollånes MC, Jenum AK, Berg TJ, Løvaas KF, Cooper JG, Sandberg S. Availability and analytical quality of hemoglobin A1c point-of-care testing in general practitioners' offices are associated with better glycemic control in type 2 diabetes. *Clin Chem Lab Med* 2020;58:1349–56.
- Berwouts S, Fanning K, Morris MA, Barton DE, Dequeker E. Quality assurance practices in Europe: a survey of molecular genetic testing laboratories. *Eur J Hum Genet* 2012;20:1118–26.
- Keppens C, Tack V, Hart N, Tembuysen L, Ryska A, Pauwels P, et al. A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer. *Oncotarget* 2018;9:24–38.
- Laudus N, Nijs L, Nauwelaers I, Dequeker E. The significance of external quality assessment schemes for molecular testing in clinical laboratories. *Cancers* 2022;14:3686.
- Buchta C, Coucke W, Mayr WR, Müller MM, Oeser R, Schweiger CR, et al. Evidence for the positive impact of ISO 9001 and ISO 15189 quality systems on laboratory performance – evaluation of immunohaematology external quality assessment results during 19 years in Austria. *Clin Chem Lab Med* 2018;56:2039–46.
- van Moort I, Joosten M, de Maat MPM, Leebeek FWG, Cnossen MH. Pitfalls in the diagnosis of hemophilia severity: what to do? *Pediatr Blood Cancer* 2017;64:e26276.
- Buchta C, Coucke W, Huf W, Griesmacher A, Müller MM, Mayr WR, et al. External quality assessment providers' services appear to more impact the immunohaematology performance of laboratories than national regulatory and economic conditions. *Clin Chem Lab Med* 2022;60:361–9.
- van Schroyen Lantman M, Grobden R, van Herwaarden AE, van Berkel M, Schaap J, Thelen M. To rule-in, or not to falsely rule-out, that is the question: evaluation of hs-cTnT EQA performance in light of the ESC-2020 guideline. *Clin Chem Lab Med* 2024;62:1158–66.
- Miller WG, Myers GL, Rej R. Why commutability matters. *Clin Chem* 2006;52:553–4.
- Fogazzi GB, Secchiero S, Garigali G, Plebani M. Evaluation of clinical cases in external quality assessment scheme (EQAS) for the urinary sediment. *Clin Chem Lab Med* 2014;52:845–52.
- Ajzner É, Rogic D, Meijer P, Kristoffersen AH, Carraro P, Sozmen E, et al. An international study of how laboratories handle and evaluate patient samples after detecting an unexpected APTT prolongation. *Clin Chem Lab Med* 2015;53:1593–603.
- BS EN 14136:2004 Use of external quality assessment schemes in the assessment of the performance of in vitro diagnostic examination procedures. Plzen, Czech Republic: European Standards s.r.o; 2004.
- Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU.
- Sandberg S, Fauskanger P, Johansen JV, Keller T, Budd J, Greenberg N, et al. Recommendations for setting a criterion and assessing commutability of sample materials used in external quality assessment/proficiency testing schemes. *Clin Chem* 2023;69:1227–37.
- Horvath AR, Lord SJ, StJohn A, Sandberg S, Cobbaert CM, Lorenz S, et al. From biomarkers to medical tests: the changing landscape of test evaluation. *Clin Chim Acta* 2014;427:49–57.
- Cobbaert CM. Implementing cardiovascular precision diagnostics: laboratory specialists as catalysts? *Ann Clin Biochem* 2023;60:151–4.
- Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2021;42:1289–367.
- Wu AHB, Christenson RH, Greene DN, Jaffe AS, Kavsak PA, Ordonez-Llanos J, et al. Clinical laboratory practice recommendations for the use of cardiac troponin in acute coronary syndrome: expert opinion from the academy of the American association for clinical chemistry and the task force on clinical applications of cardiac bio-markers of the international federation of clinical chemistry and laboratory medicine. *Clin Chem* 2018;64:645–55.
- Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 2023;44:3720–6.
- van Schroyen Lantman M, van de Logt AE, Prudon-Rosmulder E, Langelan M, Demir AY, Kurstjens S, et al. Albumin determined by

- bromocresol green leads to erroneous results in routine evaluation of patients with chronic kidney disease. *Clin Chem Lab Med* 2023;61:2167–77.
31. Fahie-Wilson MN, Cobbaert CM, Horvath AR, Smith TP. Interference by macroprolactin in assays for prolactin: will the in Vitro Diagnostics Regulation lead to a solution at last? *Clin Chem Lab Med* 2022;60:1350–5.
 32. U.S. Food and Drug Administration. Laboratory developed tests; 2023. Available from: <https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests>.
 33. Moran AB, Domínguez-Vega E, Nouta J, Pongracz T, de Reijke TM, Wuhrer M, et al. Profiling the proteoforms of urinary prostate-specific antigen by capillary electrophoresis – mass spectrometry. *J Proteomics* 2021;238:104148.
 34. Ruhaak LR, Romijn FPHTM, Smit NPM, van der Laarse A, Pieterse MM, de Maat MPM, et al. Detecting molecular forms of antithrombin by LC-MRM-MS: defining the measurands. *Clin Chem Lab Med* 2018;56:1704–14.
 35. Kruijt M, van der Pol LM, Eikenboom J, Verburg HJ, Cobbaert CM, Ruhaak LR. Unraveling a borderline antithrombin deficiency case with quantitative mass spectrometry. *J Thromb Haemostasis* 2022;20:145–8.
 36. 88 FR 68006 – Medical Devices; Laboratory Developed Tests. Department of Health and Human Services Food and Drug Administration; 2024, vol 89.
 37. U.S. Food and Drug Administration. Facts about the current good manufacturing practice (CGMP); 2024. Available from: <https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps>.
 38. Kelly JJ, Coen JA, Rich LA, Morsali D. Summary of LDT rule: an in-depth look at the final rule regarding laboratory-developed tests [Internet]; 2024. Available from: <https://www.venable.com/insights/publications/2024/05/an-in-depth-look-at-the-final-rule-regarding#:~:text=The%20U.S.%20Food%20and%20Drug,outside%20a%20laboratory%20and%20those>.
 39. Jones GRD, Delatour V, Badrick T. Metrological traceability and clinical traceability of laboratory results – the role of commutability in External Quality Assurance. *Clin Chem Lab Med* 2022;60:669–74.
 40. Ceriotti F. Prerequisites for use of common reference intervals. *Clin Biochem Rev* 2007;28:115–21.
 41. Panteghini M. Traceability, reference systems and result comparability. *Clin Biochem Rev* 2007;28:97–104.
 42. Mi W, Josephs RD, Melanson JE, Dai X, Wang Y, Zhai R, et al. PAWG pilot study on quantification of SARS-CoV-2 monoclonal antibody – part 1. *Metrologia* 2022;59:08001.
 43. Whale AS, Jones GM, Pavšič J, Dreo T, Redshaw N, Akyürek S, et al. Assessment of digital PCR as a primary reference measurement procedure to support advances in precision medicine. *Clin Chem* 2018;64:1296–307.
 44. Vierbaum L, Wojtalewicz N, Grunert HP, Lindig V, Duehring U, Drosten C, et al. RNA reference materials with defined viral RNA loads of SARS-CoV-2 – a useful tool towards a better PCR assay harmonization. Ho PL, editor. *PLoS One* 2022;17:e0262656.
 45. EQALM. HALMA – EQALM. Available from: <https://eqalm.org/cooperations/halma>.
 46. International Consortium for Harmonization of Clinical Laboratory Results. Available from: <https://www.harmonization.net/>.
 47. International Federation of Clinical Chemistry and Laboratory Medicine. SD committees – IFCC. Available from: <https://ifcc.org/ifcc-scientific-division/sd-committees/>.
 48. International Federation of Clinical Chemistry and Laboratory Medicine. SD working groups – IFCC. Available from: <https://ifcc.org/ifcc-scientific-division/sd-working-groups/>.
 49. The International Federation of Clinical Chemistry and Laboratory Medicine. Traceability in laboratory medicine (C-TLM) – IFCC. Available from: <https://ifcc.org/ifcc-scientific-division/sd-committees/c-tlm/>.
 50. JCTLM Accurate results for patient care. Available from: <https://jctlm.org/>.
 51. JCTLM Accurate results for patient care. JCTLM Database. Available from: <https://www.jctlmdb.org/#/app/home>.
 52. Morris C, Govind S, Fryer J, Almond N. SoGAT – 25 years of improving the measurement of nucleic acids in infectious disease diagnostics (a review). *Metrologia* 2019;5:044007.
 53. Huynh HH, Bœuf A, Derbez-Morin M, Dupuy AM, Lalere B, Delatour V, et al. Development of an antibody-free ID-LC MS method for the quantification of procalcitonin in human serum at sub-microgram per liter level using a peptide-based calibration. *Anal Bioanal Chem* 2021;413:4707–25.
 54. Milavec M, Pavšič J, Bogožalec Košir A, Jones GM, O'Sullivan DM, Devonshire AS, et al. The performance of human cytomegalovirus digital PCR reference measurement procedure in seven external quality assessment schemes over four years. *Methods* 2022;201:65–73.
 55. van Rossum HH, Holdenrieder S, Ballieux BEPB, Badrick TC, Yun YM, Zhang C, et al. Investigating the current harmonization status of tumor markers using global external quality assessment programs: a feasibility study. *Clin Chem* 2024;70:669–79.
 56. EFI – European Federation for Immunogenetics. Available from: <https://efi-web.org/about-efi>.
 57. Buchta C, Gidske G, Henriksen GM, Badrick T. European organisation of external quality assurance providers in laboratory medicine (EQALM). The European organisation of external quality assurance providers in laboratory medicine (EQALM) statement: guidelines for publishing about interlaboratory comparison studies (PubLIC). *Crit Rev Clin Lab Sci* 2024;61:588–98.
 58. Regulatory Focus. The essential list of regulatory authorities in Europe; 2020. Available from: <https://www.raps.org/News-and-Articles/News-Articles/2020/1/The-Essential-List-of-Regulatory-Authorities-in-Eu>.
 59. Wielders JPM, Porpiglia NM, Schellenberg F, Deenmamode J, Delanghe J, Anton RF, et al. Group on CDT standardisation. *Clin Chim Acta* 2024;555:117800.
 60. Centres for Disease Control and Prevention. Clinical laboratory improvement Amendments (CLIA). Available from: <https://www.cdc.gov/clia/index.html>.
 61. Qualitätssicherung laboratoriumsmedizinischer Untersuchungen – Rili-BÄK. Available from: https://www.instand-ev.de/fileadmin/user_upload/_Bek_BAEK_RiLi_BAEK_ONLINE_FINAL_VERS_26_05_2023.pdf.
 62. Badrick T, Jones G, Miller WG, Panteghini M, Quintenz A, Sandberg S, et al. Differences between educational and regulatory external quality assurance/proficiency testing schemes. *Clin Chem* 2022;68:1238–44.
 63. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Available from: <http://data.europa.eu/eli/dir/1998/79/oj>.
 64. ISO 17511:2020 In vitro diagnostic medical devices – requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples. Geneva: International Organization for Standardization (ISO); 2020.

65. ISO/IEC 17025:2017 General requirements for the competence of testing and calibration laboratories. Geneva: International Organization for Standardization (ISO); 2017.
66. ISO 15195:2018 Laboratory medicine – requirements for the competence of calibration laboratories using reference measurement procedures. Geneva: International Organization for Standardization (ISO); 2018.
67. ISO 15194:2009 In vitro diagnostic medical devices – measurement of quantities in samples of biological origin – requirements for certified reference materials and the content of supporting documentation. Geneva: International Organization for Standardization (ISO); 2009.
68. Kessler A, Siekmann L, Weykamp C, Geilenkeuser WJ, Dreazen O, Middle J, et al. External quality assessment scheme for reference laboratories – review of 8 years' experience. *Clin Chem Lab Med* 2013; 5:997–1005.
69. Joore M, Grimm S, Boonen A, de Wit M, Guillemin F, Fautrel B. Health technology assessment: a framework. *RMD Open* 2020;6: e001289.
70. O'Rourke B, Oortwijn W, Schuller T, International Joint Task Group. The new definition of health technology assessment: a milestone in international collaboration. *Int J Technol Assess Health Care* 2020;36: 187–90.
71. Radley-Gardner O, Beale H, Zimmermann R, editors. Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU. Fundamental texts on European private law. Oxford: Hart Publishing; 2016.
72. Smith AF, Messenger M, Hall P, Hulme C. The role of measurement uncertainty in health technology assessments (HTAs) of in vitro tests. *Pharmacoeconomics* 2018;36:823–35.
73. Buchta C, Zeichhardt H, Badrick T, Coucke W, Wojtalewicz N, Griesmacher A, et al. Classification of “Near-patient” and “Point-of-Care” SARS-CoV-2 Nucleic Acid Amplification Test Systems and a first approach to evaluate their analytical independence of operator activities. *J Clin Virol* 2023;165:105521.
74. Vierbaum L, Wojtalewicz N, Grunert HP, Zimmermann A, Scholz A, Goseberg S, et al. Results of German external quality assessment schemes for SARS-CoV-2 antigen detection. *Sci Rep* 2023;13:13206.
75. Donoso Mantke O, Corman VM, Taddei F, McCulloch E, Niemeyer D, Grumiro L, et al. Importance of external quality assessment for SARS-CoV-2 antigen detection during the COVID-19 pandemic. *J Clin Virol* 2022;154:105222.
76. Buchta C, Aberle SW, Görzer I, Griesmacher A, Müller MM, Neuwirth E, et al. External quality assessments for SARS-CoV-2 genome detection in Austria: a comparison of the first postpandemic round with results from the pandemic era. *Wien Klin Wochenschr* 2024;136:429–38.
77. Görzer I, Buchta C, Chiba P, Benka B, Camp JV, Holzmann H, et al. First results of a national external quality assessment scheme for the detection of SARS-CoV-2 genome sequences. *J Clin Virol* 2020;129: 104537.
78. Zeichhardt H, Kammel M. Kommentar zum Extra Ringversuch Gruppe 340 Virusgenom-Nachweis – SARS-CoV-2 [INSTAND report on extra EQAS group no. 340 virus genome detection SARS-CoV-2]. Düsseldorf/Berlin: INSTAND; 2020. Available from: <https://www.instand-ev.de/System/rv-files/340%20DE%20SARS-CoV-2%20Genom%20April%202020%20200502j.pdf>.
79. Sung H, Yoo CK, Han MG, Lee SW, Lee H, Chun S, et al. Preparedness and rapid implementation of external quality assessment helped quickly increase COVID-19 testing capacity in the Republic of Korea. *Clin Chem* 2020;66:979–81.
80. Matheussen V, Corman VM, Donoso Mantke O, McCulloch E, Lammens C, Goossens H, et al. International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020. *Euro Surveill* 2020;25:2001223.
81. Zeichhardt H, Kammel M. INSTAND report on extra EQAS group no. 340 virus genome detection SARS-CoV-2. Düsseldorf/Berlin: INSTAND; 2020. Available from: <https://www.instand-ev.de/System/rv-files/340%20EN%20SARS-CoV-2%20Genom%20April%202020%20200502j.pdf>.
82. Sung H, Han MG, Yoo CK, Lee SW, Chung YS, Park JS, et al. Nationwide external quality assessment of SARS-CoV-2 molecular testing, South Korea. *Emerg Infect Dis* 2020;26:2353–60.
83. Evans D, Cowen S, Kammel M, O'Sullivan DM, Stewart G, Grunert HP, et al. The dangers of using Cq to quantify nucleic acid in biological samples: a lesson from COVID-19. *Clin Chem* 2021;68:153–62.
84. Buchta C, Görzer I, Chiba P, Camp JV, Holzmann H, Puchhammer-Stöckl E, et al. Variability of cycle threshold values in an external quality assessment scheme for detection of the SARS-CoV-2 virus genome by RT-PCR. *Clin Chem Lab Med* 2021;59:987–94.
85. Buchta C, Camp JV, Jovanovic J, Chiba P, Puchhammer-Stöckl E, Mayerhofer M, et al. The versatility of external quality assessment for the surveillance of laboratory and in vitro diagnostic performance: SARS-CoV-2 viral genome detection in Austria. *Clin Chem Lab Med* 2021;59:1735–44.
86. Park K, Sung H, Chun S, Min WK. Evaluation of intra- and interlaboratory variations in SARS-CoV-2 real-time RT-PCR through nationwide proficiency testing. *Lab Med* 2022;53:636–9.
87. Buchta C, Kollros D, Jovanovic J, Huf W, Delatour V, Puchhammer-Stöckl E, et al. Converting to an international unit system improves harmonization of results for SARS-CoV-2 quantification: results from multiple external quality assessments. *J Clin Virol* 2023;158:105352.
88. Restelli V, Vimalanathan S, Sreya M, Noble MA, Perrone LA. Ensuring diagnostic testing accuracy for patient care and public health-COVID-19 testing scale-up from an EQA provider's perspective. *PLOS Glob Public Health* 2023;3:e0001615.
89. Buchta C, Springer D, Jovanovic J, Borsodi C, Weidner L, Sareban N, et al. Three rounds of a national external quality assessment reveal a link between disharmonic anti-SARS-CoV-2 antibody quantifications and the infection stage. *Clin Chem Lab Med* 2023;61:1349–58.
90. Buchta C, Camp JV, Jovanovic J, Radler U, Puchhammer-Stöckl E, Benka B, et al. A look at the precision, sensitivity and specificity of SARS-CoV-2 RT-PCR assays through a dedicated external quality assessment round. *Clin Chem Lab Med* 2022;60:e34–7.
91. Buchta C, Camp JV, Jovanovic J, Puchhammer-Stöckl E, Strassl R, Müller MM, et al. Results of a SARS-CoV-2 virus genome detection external quality assessment round focusing on sensitivity of assays and pooling of samples. *Clin Chem Lab Med* 2022;60:1308–12.
92. Aussagekraft und Bedeutung von Ringversuchen zum Nachweis von SARS-CoV-2. Hier: INSTAND-Ringversuch zum „Virusgenom-Nachweis – SARS-CoV-2“ im April 2020: Beurteilung der PCR-Ergebnisse [Significance and importance of round robin tests for verification from SARS-CoV-2. Here: INSTAND round robin test for “virus genome detection – SARS-CoV-2” in April 2020: Evaluation of the PCR results]. Düsseldorf; 2020. Available from: https://www.instand-ev.de/fileadmin/uploads/Aktuelles/Konsentiertere_Stellungnahme_zum_INSTAND_RV_340_SARS-CoV-2_NAT_April_2020_bt.pdf [Accessed 3 May 2023].
93. Sachs JD, Karim SSA, Akin L, Allen J, Brosbøl K, Colombo F, et al. The Lancet Commission on lessons for the future from the COVID-19 pandemic. *Lancet* 2022;400:1224–80.

94. Buchta C, Zeichhardt H, Griesmacher A, Schellenberg I, Kammel M. Ignoring SARS-CoV-2 testing performance during COVID-19. *Lancet Microbe* 2023;4:e296.
95. Buchta C, Zeichhardt H, Osterman A, Perrone LA, Griesmacher A. Do not blindly trust negative diagnostic test results. *Lancet Microbe* 2024; 5:e102–3.
96. Buchta C, Zeichhardt H, Aberle SW, Camp JV, Görzer I, Weseslindtner L, et al. Design of external quality assessment schemes and definition of the roles of their providers in future epidemics. *Lancet Microbe* 2023; 4:e552–62.
97. Promequalab – Projeto de Melhoria da Qualidade Laboratorial para Países de Língua Portuguesa [Internet]. Available from <https://promequalab.org.cv/>.
98. Gidske G, Aakre KM, Rustad P, Sandberg S, Norling A, Pelanti J, et al. Handling of hemolyzed serum samples in clinical chemistry laboratories: the Nordic hemolysis project. *Clin Chem Lab Med* 2019; 57:1699–711.
99. Jassam N, Weykamp C, Thomas A, Secchiero S, Sciacovelli L, Plebani M, et al. Post-standardization of routine creatinine assays: are they suitable for clinical applications. *Ann Clin Biochem* 2017;54:386–94.
100. Dimech W, Cabuang LM, Grunert HP, Lindig V, James V, Senechal B, et al. Results of cytomegalovirus DNA viral loads expressed in copies per millilitre and international units per millilitre are equivalent. *J Virol Methods* 2018;252:15–23.
101. Arnaud J, Patriarca M, Fofou-Caillierez BM, González-Estecha M, Gómez MG, De Graaf I, et al. External quality assessment schemes for inorganic elements in the clinical laboratory: lessons from the OELM scheme. *J Trace Elem Med Biol* 2020;59:126414.
102. Occupational and Environmental Laboratory Medicine. Organisers of EQAS for occupational and environmental laboratory medicine. Available from: <https://www.trace-elements.eu/>.
103. Bullock DG, Dumont G, Vassault A, Aguzzi F, Chambers RE, Milford WA, et al. Immunochemical assays of serum proteins: a European external quality assessment survey and the effects of calibration procedures on interlaboratory agreement. *Clin Chim Acta* 1990;187:21–35.
104. Johnson AM, Whicher JT. Effect of certified reference material 470 (CRM 470) on national quality assurance programs for serum proteins in Europe. *Clin Chem Lab Med* 2001;39:1123–8.
105. Weykamp C, John WG, English E, Erasmus RT, Sacks DB, Buchta C, et al, The EurA1c Trial Group. EurA1c: the European HbA1c trial to investigate the performance of HbA1c assays in 2166 laboratories across 17 countries and 24 manufacturers by use of the IFCC model for quality targets. *Clin Chem* 2018;64:1183–92.